Clene Inc. (CLNN) vs Xilio Therapeutics, Inc. (XLO)

Clene Inc. and Xilio Therapeutics, Inc. are both Biotechnology companies. Clene Inc. and Xilio Therapeutics, Inc. are of similar size ($59.8M and $59.2M). Xilio Therapeutics, Inc. grew revenue faster over the last twelve months: 327.3% against −31.1%. Xilio Therapeutics, Inc. has the higher net margin (−34.1% vs −20,059.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Xilio Therapeutics, Inc. leads on 11 and Clene Inc. on 4.

Valuation

Metric CLNN XLO Biotechnology median
P/E n/m n/m 7.88
P/S 270.29 2.74 11.47
P/B n/m 2.43 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 314.15 0.75 10.73
Earnings yield (81.40%) (16.49%) (28.84%)
Free cash flow yield (29.95%) (34.93%) (23.03%)

Profitability

Metric CLNN XLO Biotechnology median
Gross margin 70.05% 100.00% 65.16%
Operating margin (10,431.98%) (48.94%) 0.00%
Net margin (20,059.90%) (34.06%) 0.00%
Free cash flow margin (8,095.43%) (95.59%) 0.00%
Return on equity 237.15% (55.03%) (57.72%)
Return on assets (174.99%) (15.16%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CLNN XLO Biotechnology median
Revenue growth (TTM) (31.12%) 327.25% 5.64%
EPS growth (last fiscal year) 53.26% 72.55% —
Revenue growth, 5-year CAGR (22.66%) — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLNN XLO Biotechnology median
Debt to equity (0.74) 0.00 0.00
Current ratio 3.07 4.25 4.73
Net debt to EBITDA (0.39) 3.40 0.96

Dividend

Metric CLNN XLO Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CLNN XLO Biotechnology median
Market cap 59.84m 59.22m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack